# A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT02174172** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 158 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Interferon alfa-2b
- **DRUG:** Ipilimumab
- **DRUG:** Obinutuzumab
- **DRUG:** PEG-interferon alfa-2a

## Key facts

- **NCT ID:** NCT02174172
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-18
- **Primary completion:** 2019-11-25
- **Final completion:** 2019-11-25
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174172, "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02174172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*